Drug intelligence / Profile preview

QL-801

Development stage: Preclinical
Lead developer: AliveGen
Modality: Small Molecules
Administration: Transdermal

Overview

QL-801 is a small molecule alpha-2 adrenergic receptor agonist being developed by BioQingLam for the treatment of insomnia. The drug is formulated as a transdermal soluble microneedle patch, utilizing the company's proprietary delivery technology to potentially improve patient compliance and drug absorption. By acting as an agonist at alpha-2 adrenergic receptors, QL-801 is designed to provide sedative and hypnotic effects. It is currently in the investigator-initiated trial (IIT) stage of development.

Targets

ADRA2A (α2A)

Beyond the preview

Go deeper on QL-801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QL-801.

Explore the full profile